Article

Phase III dry eye treatment study completed

ProTrials Research has completed a large phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease.

 

Sunnyvale, CA-ProTrials Research has completed a large phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease.

In the last 3 years, ProTrials has conducted four phase III dry eye studies, and multiple phase III trials across a broad range of therapeutic areas involving over 100 sites and 1,000 patients, according to the company.

“ProTrials offers experience in many therapeutic areas, but our ability to handle the intricacies required in ophthalmology studies is key to our repeated success in this type of research,” said Inger Arum, president of ProTrials.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
© 2025 MJH Life Sciences

All rights reserved.